Article Text

Download PDFPDF

Melatonin: prescribing practices and adverse events
  1. D L Waldron1,
  2. D Bramble2,
  3. P Gringras3
  1. 1Harper House Children’s Services, Radlett, Herts, UK
  2. 2Telford & Wrekin PCT, Longbow House, Harlescott Lane, Shrewsbury, UK
  3. 3The Newcomen Centre, Guy’s Hospital, London, UK
  1. Correspondence to:
    Dr P Gringras
    The Newcomen Centre, Guy’s Hospital, London, UK;

Statistics from

Melatonin is currently an unlicensed, “named patient only” medicine in the UK, although it is available as a dietary supplement in the United States and over the internet. It is used for a variety of sleep disorders in children who often have neurodevelopmental impairments.1,2 There remains a dearth of robust randomised controlled trials to demonstrate its efficacy, while lack of pharmacokinetic, pharmacodynamics, and toxicology data limits knowledge of therapeutic dose ranges, formulations, and adverse effects.

We carried out an anonymous questionnaire survey to examine prescribing practices of members of the British Association for Community Child Health (BACCH) and the British Academy …

View Full Text

Supplementary materials

  • The appendix is available as a downloadable PDF (printer friendly file).

    If you do not have Adobe Reader installed on your computer,
    you can download this free-of-charge, please Click here


    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.